最畅销癌症药物名单 罗氏独占鳌头
2014-03-17 09:21 来源：丁香园 作者：fyc5078
2013年，制药行业20款最畅销癌症药物总共产生530亿美元的销售额，罗氏美罗华（利妥昔单抗）、阿瓦斯汀和赫赛汀将继续扩大它们在排行榜中的领先地位。这三款药物的销售额总计约有210亿美元，约占TOP20癌症药物销售总额的大约40%。如果把特罗凯和希罗达也考虑在内，那么这一名单中的罗氏产品在2013年销售了大约240亿美元。
预期到2018年，特罗凯和希罗达在20款最畅销癌症药物中均不会起到举足轻重的作用，但基于当前的一致预测，罗氏的Perjeta、Kadcyla和Gazyva专营权预期将会起到重要作用。最主要的是赫赛汀与美罗华的这些后继产品到2018年将会达到什么样的地位。
看一下2018年的预期排名，这一名单显示目前处于关键研究阶段的癌症免疫治疗药物将会迅速崛起。到2018年，百时美施贵宝的Nivolumab预期将产生大约25亿美元的销售额，默沙东MK-3475的销售额可能会略低于20亿美元。百时美施贵宝已上市免疫治疗药物伊匹单抗的销售额预期也会在未来五年内翻番，伊匹单抗与Nivolumab的合并使用在某种程度上会对其增长起到推动作用。
预期在未来五年，强生也会作为癌症药物的新玩家闪亮登场，这主要靠其对Imbruvica的积极吸纳。与2013年20款最畅销产品所产生的530亿美元销售额相比，那些列入2018年最畅销药物名单中的产品，预期将产生大约700亿美元的总销售额。一个有趣的趋势是，重磅炸弹级癌症药物的数量会有明显的增加，将从18个跳涨到29个。
信源地址：http://www.daodoc.com/node/1195713?tsid=28#axzz2vw0jyrkG
FirstWord Lists – The best-selling cancer drugs in 2013 and 2018: Roche dominates while immunotherapies, Johnson & Johnson emerge as contenders
(Ref: FirstWord Lists) March 14th, 2014 By: Simon King
The industry\'s 20 biggest-selling cancer drugs generated combined sales of $53 billion in 2013, with Roche\'s Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table.With combined sales of around $21 billion, these three drugs alone accounted for approximately 40 percent of the combined value of the 20 biggest-selling products.Factoring in the Tarceva and Xeloda brands, Roche generated 2013 sales of around $24 billion from products included on the list.By 2018, neither the Tarceva or Xeloda brands are expected to feature among the 20 biggest-selling cancer drugs, however, Roche\'s Perjeta, Kadcyla and Gazyva franchises are expected to feature based on current consensus forecasts.Most impreive are the lofty positions that these succeor products to Herceptin and Rituxan are set to reach by 2018Pharmacyclics, Johnson & Johnson\'s newest drug profiled
In Focus: How Johnson & Johnson\'s pharma growth is laying the foundations for long-term succe
ViewPoints: Medivation forced into a waiting game – will it PREVAIL?
Physician Views Poll Results – Medivation\'s Xtandi set to slot seamlely into pre-chemotherapy prostate cancer market ahead of Johnson & Johnson\'s Zytiga, indicate urologists and oncologists
Versus the $53 billion sales generated by the top 20 products in 2013, those products positioned as the industry\'s biggest selling in 2018 are forecast to deliver combined revenues of around $70 billion.One interesting trend is a notable jump in the number of blockbuster cancer products between these two time points, which jumps from 18 to 29.
